335 related articles for article (PubMed ID: 22143115)
1. Herpes simplex virus-2 in the genital mucosa: insights into the mucosal host response and vaccine development.
Lee AJ; Ashkar AA
Curr Opin Infect Dis; 2012 Feb; 25(1):92-9. PubMed ID: 22143115
[TBL] [Abstract][Full Text] [Related]
2. Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa.
Chan T; Barra NG; Lee AJ; Ashkar AA
J Reprod Immunol; 2011 Mar; 88(2):210-8. PubMed ID: 21334750
[TBL] [Abstract][Full Text] [Related]
3. Induction of innate immune responses in the female genital tract: friend or foe of HIV-1 infection?
Firoz Mian M; Ashkar AA
Am J Reprod Immunol; 2011 Mar; 65(3):344-51. PubMed ID: 21223417
[TBL] [Abstract][Full Text] [Related]
4. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.
Milligan GN; Bernstein DI
Virology; 1995 Oct; 212(2):481-9. PubMed ID: 7571418
[TBL] [Abstract][Full Text] [Related]
5. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2.
Milligan GN; Bernstein DI; Bourne N
J Immunol; 1998 Jun; 160(12):6093-100. PubMed ID: 9637526
[TBL] [Abstract][Full Text] [Related]
6. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice.
Tengvall S; Harandi AM
J Reprod Immunol; 2008 Jun; 78(1):49-57. PubMed ID: 17945349
[TBL] [Abstract][Full Text] [Related]
7. Adaptive immune responses fail to provide protection against genital HSV-2 infection in the absence of IL-15.
Gill N; Ashkar AA
Eur J Immunol; 2007 Sep; 37(9):2529-38. PubMed ID: 17668897
[TBL] [Abstract][Full Text] [Related]
8. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice.
Vagvala SP; Thebeau LG; Wilson SR; Morrison LA
J Virol; 2009 Jan; 83(2):953-60. PubMed ID: 18987142
[TBL] [Abstract][Full Text] [Related]
9. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.
Gill N; Deacon PM; Lichty B; Mossman KL; Ashkar AA
J Virol; 2006 Oct; 80(20):9943-50. PubMed ID: 17005672
[TBL] [Abstract][Full Text] [Related]
10. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
[TBL] [Abstract][Full Text] [Related]
11. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL
Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530
[TBL] [Abstract][Full Text] [Related]
12. Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8
Lopes PP; Todorov G; Pham TT; Nesburn AB; Bahraoui E; BenMohamed L
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437976
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of interleukin-15 compromises CD4-dependent adaptive immune responses against herpes simplex virus 2.
Gill N; Ashkar AA
J Virol; 2009 Jan; 83(2):918-26. PubMed ID: 19004955
[TBL] [Abstract][Full Text] [Related]
14. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
[TBL] [Abstract][Full Text] [Related]
15. Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract.
Tang VA; Rosenthal KL
J Reprod Immunol; 2010 Dec; 87(1-2):39-44. PubMed ID: 20688399
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes.
Kim M; Osborne NR; Zeng W; Donaghy H; McKinnon K; Jackson DC; Cunningham AL
J Immunol; 2012 May; 188(9):4158-70. PubMed ID: 22467654
[TBL] [Abstract][Full Text] [Related]
17. Protective immunity to genital herpes simplex [correction of simpex] virus type 2 infection is mediated by T-bet.
Svensson A; Nordström I; Sun JB; Eriksson K
J Immunol; 2005 May; 174(10):6266-73. PubMed ID: 15879125
[TBL] [Abstract][Full Text] [Related]
18. Development of a therapeutic vaccine for HSV-2.
Hosken NA
Vaccine; 2005 Mar; 23(17-18):2395-8. PubMed ID: 15755634
[TBL] [Abstract][Full Text] [Related]
19. The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection.
Gill N; Davies EJ; Ashkar AA
Am J Reprod Immunol; 2008 Jan; 59(1):35-43. PubMed ID: 18154594
[TBL] [Abstract][Full Text] [Related]
20. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
Gill N; Rosenthal KL; Ashkar AA
J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
